AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Baker Tilly Wealth Management LLC

Baker Tilly Wealth Management LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 14.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 9,465 shares of the company’s stock after purchasing an additional 1,165 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in AstraZeneca were worth $620,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. Martin Investment Management LLC grew its position in shares of AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC lifted its stake in AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares in the last quarter. Creative Planning boosted its holdings in AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after buying an additional 16,692 shares during the last quarter. Soros Fund Management LLC raised its holdings in shares of AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after acquiring an additional 201,233 shares during the last quarter. Finally, Optas LLC boosted its stake in shares of AstraZeneca by 173.5% in the third quarter. Optas LLC now owns 15,570 shares of the company’s stock worth $1,213,000 after acquiring an additional 9,877 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 1.3 %

Shares of AZN stock traded up $0.86 during trading on Friday, hitting $67.44. 1,614,751 shares of the stock traded hands, compared to its average volume of 3,565,128. The firm’s fifty day moving average price is $66.20 and its 200-day moving average price is $75.01. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market capitalization of $209.11 billion, a P/E ratio of 32.27, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.87 EPS. As a group, research analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.